Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

von Minckwitz, Gunter

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. [electronic resource] - The New England journal of medicine Jan 2012 - 299-309 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1533-4406

10.1056/NEJMoa1111065 doi


Adult
Aged
Angiogenesis Inhibitors--administration & dosage
Antibodies, Monoclonal, Humanized--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Bevacizumab
Breast Neoplasms--drug therapy
Cyclophosphamide--administration & dosage
Disease Progression
Epirubicin--administration & dosage
Female
Humans
Logistic Models
Mastectomy, Segmental
Medication Adherence
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Receptor, ErbB-2